Johnson & Johnson announced new data from its oncology pipeline at the 2025 European Lung Cancer Congress, highlighting the Phase 3 MARIPOSA study results. The study showed that RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) significantly outperformed the standard-of-care treatment, osimertinib, for patients with EGFR-mutated non-small cell lung cancer. The combination therapy is projected to improve overall survival by more than a year, offering a major breakthrough in first-line treatment.

Additional findings included results from the Phase 2 COCOON study, which demonstrated that a proactive dermatologic regimen improved patient experience by reducing skin-related side effects. The company also presented data from the Phase 2 PALOMA-2 study, which supports the feasibility of switching patients to subcutaneous amivantamab administration.

The results reinforce Johnson & Johnson's focus on developing chemotherapy-free regimens that extend survival and improve the quality of life for lung cancer patients. The findings may reshape treatment discussions and set new standards for EGFR-targeted therapies.